generation run 2026-04-28
69 min completedmodel pipeline-v5plan not recordedrun/912c1417…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- taper_silent
- safety_gap
Reproduce
- inputs
- 47 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
25 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | zolpidem hallucinations parasomnias sleepwalking complex behaviors adverse effects | 1 | 1 | FDA adverse event analysis for zolpidem complex sleep behaviors |
| 2 | OpenAlex | zolpidem pharmacokinetics sex differences gender (citations sort) | 8 | 1 | Key review establishing sex-specific PK differences that led to FDA dose change for zolpidem |
| 3 | PubMed | zolpidem dependence abuse withdrawal tolerance | 10 | 3 | Reviews and primary research on zolpidem dependence, tolerance, abuse |
| 4 | PubMed | zolpidem overdose toxicity adverse effects case report | 3 | 2 | First overdose case report is historically important; withdrawal case report documents symptom profile |
| 5 | OpenAlex | zolpidem pharmacology GABA receptor (citations sort) | 10 | 2 | Clinical practice guidelines and meta-analyses directly relevant to zolpidem clinical use |
| 6 | PubMed | zolpidem GABA-A receptor binding pharmacology mechanism | 10 | 4 | Selected papers directly relevant to zolpidem GABA-A receptor binding, mechanism, and tolerance |
| 7 | PubMed | zolpidem sleep architecture polysomnography clinical study | 10 | 3 | Studies on zolpidem's effects on sleep stages and cognitive performance |
| 8 | ClinicalTrials.gov | zolpidem insomnia | 10 | 3 | Trials directly involving zolpidem as treatment arm or comparator |
| 9 | PubChem | zolpidem | 1 | 1 | Core chemical identity data for zolpidem |
| 10 | PubMed | zolpidem pharmacokinetics absorption distribution elimination half-life | 1 | 1 | Key pharmacokinetics data with sex differences |
| 11 | PubMed | zolpidem abuse potential recreational misuse euphoria | 1 | 1 | Key quantitative abuse potential data showing hallucinations and euphoria at supratherapeutic doses |
| 12 | WebSearch | zolpidem history discovery synthesis Ambien FDA approval 1992 Sanofi schedule IV | 10 | 2 | Historical and regulatory context not available via PubMed |
| 13 | WebSearch | zolpidem FDA 2013 label change dose reduction women 5mg driving impairment NEJM | 10 | 2 | Critical regulatory event for zolpidem dosing recommendations |
| 14 | PubMed | zolpidem disorders of consciousness minimally conscious paradoxical stimulant | 1 | 1 | Documents the paradoxical stimulant effect of zolpidem in brain-injured patients |
| 15 | PubMed | zolpidem CYP3A4 metabolism cytochrome P450 drug interaction | 8 | 3 | Core CYP metabolism and drug interaction data |
| 16 | WebSearch | zolpidem legal status UK Australia Canada international controlled substance | 10 | 4 | International legal status data for legal section |
| 17 | OpenAlex | zolpidem omega-1 selectivity binding affinity Ki (citations sort) | 6 | 1 | In vivo binding selectivity data for zolpidem at alpha1 subunit |
| 18 | StatPearls/NCBI Bookshelf | zolpidem pharmacology clinical use overdose | 1 | 1 | Comprehensive clinical reference for special populations, contraindications, adverse effects |
| 19 | WebSearch | zolpidem pharmacokinetics bioavailability protein binding half-life metabolism | 10 | 2 | Comprehensive PK data including CYP enzyme contribution percentages |
| 20 | PubMed | PMID 8521677 | 1 | 1 | Foundational pharmacokinetics and pharmacodynamics review |
| 21 | WebSearch | zolpidem SMILES molecular structure melting point solubility physical properties DrugBank | 10 | 2 | Physical property data not available via structured API |
| 22 | PubMed | zolpidem withdrawal syndrome seizure | 1 | 1 | Critical safety data: high-dose withdrawal seizures |
| 23 | PubMed | zolpidem tolerance hypnotic effects duration long-term | 4 | 2 | Long-term efficacy and tolerance data; no rebound insomnia critical finding |
| 24 | PubMed/OpenAlex | zolpidem Z-drug non-benzodiazepine review clinical | 8 | 2 | Systematic reviews of Z-drug safety profile including falls, fractures, dementia |
| 25 | PubMed | zolpidem elderly cognitive impairment falls hospital risk adverse events | 1 | 1 | Fall risk data in vulnerable population |
119 claims by section — every cited sentence, checked against its source
safety35 · 24 ok
Claim in safety — inconclusiveinconclusiveworking →
The first reported zolpidem overdose case presented with profound but short-lasting coma, pinpoint pupils, and respiratory depression mimicking opioid overdosesupported
First reported case of zolpidem poisoning. Profound but short-lasting coma, pinpoint pupils, respiratory depression. Not reversed by naloxone; dramatically reversed by flumazenil. pmid:2111156
Debailleul et al. reported a subsequent case of voluntary intoxication combining zolpidem with prothipendyl and ethanol, in which respiratory depression was similarly corrected by flumazenil.supported
Voluntary intoxication with zolpidem, prothipendyl, and ethanol. Flumazenil corrected respiratory depression. pmid:1675298
Overdose management: Supportive care (airway management, intravenous fluids, cardiorespiratory monitoring). Flumazenil IV is the specific reversal agent for BZ-site occupancysupported
Dramatically reversed by flumazenil. pmid:2111156
Persistent cognitive impairment: Psychomotor, attentional, and memory deficits during nighttime awakening do not resolve with repeated dosing — tolerance to these impairments does not develop over approximately one month of nightly extended-release use.supported
ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use. a0025237
Falls and fractures: Disproportionate risk in elderly patients. Glass et al. found in a meta-analysis that the absolute benefits of sedative hypnotics in older adults were small, while fall and cognitive impairment risks were clinically significant. Brandt and Leong reviewed epidemiologic evidence confirming Z-drug association with falls, fractures, and motor vehicle accidents. Assimon and Flythe demonstrated increased fall-related fracture risk with zolpidem initiation in hemodialysis patients.supported
Meta-analysis: sedative hypnotics including zolpidem improve sleep statistically but magnitude small. Increased adverse event risk (falls, cognitive impairment) in over-60s. bmj.38623.768588.47
Falls and fractures: Disproportionate risk in elderly patients. Glass et al. found in a meta-analysis that the absolute benefits of sedative hypnotics in older adults were small, while fall and cognitive impairment risks were clinically significant. Brandt and Leong reviewed epidemiologic evidence confirming Z-drug association with falls, fractures, and motor vehicle accidents. Assimon and Flythe demonstrated increased fall-related fracture risk with zolpidem initiation in hemodialysis patients.supported
Review of major adverse events: motor vehicle accidents, falls/fractures in elderly, potential associations with dementia, infections, respiratory disease, pancreatitis, cancer. s40268-017-0207-7
Claim in safety — inconclusiveinconclusiveworking →
Flumazenil (BZ-site competitive antagonist) fully reverses zolpidem's effects and serves as both a diagnostic tool and therapeutic intervention in overdose.supported
Not reversed by naloxone; dramatically reversed by flumazenil. pmid:2111156
Cognitive decline: The association between Z-drug use and dementia risk remains under investigation. Guo et al. found that Z-drug use was not independently associated with global cognitive impairment in middle-aged and older outpatients with chronic insomnia, unlike benzodiazepine use. Brandt and Leong note that the dementia association requires further study.supported
Z-drugs (zolpidem, zopiclone) not associated with global cognitive impairment in chronic insomnia outpatients; Z drug use positively associated with attention. BZD exposure density was independent risk factor for cognitive impairment. fnhum.2021.775144
Cognitive decline: The association between Z-drug use and dementia risk remains under investigation. Guo et al. found that Z-drug use was not independently associated with global cognitive impairment in middle-aged and older outpatients with chronic insomnia, unlike benzodiazepine use. Brandt and Leong note that the dementia association requires further study.supported
Review of major adverse events: motor vehicle accidents, falls/fractures in elderly, potential associations with dementia, infections, respiratory disease, pancreatitis, cancer. s40268-017-0207-7
Claim in safety — inconclusiveinconclusiveworking →
Zolpidem is associated with complex neuropsychiatric behaviors occurring during or immediately after sleep, including somnambulism (sleepwalking), sleep-eating with amnesia, sleep-driving (operating a motor vehicle with no subsequent memory), sleep-conversation, and sleep self-intoxication (taking additional medication while asleep)supported
Complex sleep-related behaviours with zolpidem including sleepwalking, sleep eating, sleep conversation, and sleep driving documented. GABA-A agonism at alpha1 implicated. s00414-014-0997-x
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Combined administration with imipramine has been documented to potentiate anterograde amnesia.supported
Anterograde amnesia noted with imipramine combination. pmid:8521677
At therapeutic doses (5–10 mg), no tolerance to the hypnotic effect develops over 27 consecutive nights of treatmentsupported
27-night RCT: zolpidem 10mg vs triazolam 0.5mg vs placebo. Zolpidem effective; no rebound insomnia on withdrawal (unlike triazolam); no tolerance detected. pmid:7972349
However, tolerance to sedative effects does develop with chronic high-dose use, requiring dose escalation for euphoric effects.supported
Two cases: doses 200-400 mg/night and 400-500 mg/day for euphoria. pmid:21448102
The dissociation between hypnotic tolerance (absent at therapeutic doses) and cognitive tolerance (also absent) creates a paradox: patients maintain sleep-promoting benefit but do not adapt to the cognitive impairments produced during nighttime awakening.supported
ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use. a0025237
Claim in safety — inconclusiveinconclusiveworking →
Wright et al. demonstrated in mice that repeated zolpidem produces behavioral tolerance and withdrawal-like symptoms comparable to diazepam, despite zolpidem's purported lower dependence potential.supported
Repeated zolpidem produces tolerance and withdrawal-like symptoms similar to benzodiazepines despite purported lower dependence. Mouse model. s00213-014-3473-x
Withdrawal symptoms include anxiety, insomnia, restlessness, paresthesia, and flu-like symptoms, progressing to tonic seizures in severe casespartially supported
Abrupt discontinuation produced anxiety, insomnia, restlessness, tonic seizure. pmid:21448102
Withdrawal symptoms include anxiety, insomnia, restlessness, paresthesia, and flu-like symptoms, progressing to tonic seizures in severe casessupported
Withdrawal symptom timeline: anxiety, craving, paresthesia, flu-like symptoms progressing to seizures and hallucinations. fpsyt.2022.962836
Wang et al. described two cases of extreme dependence involving 200–400 mg/night and 400–500 mg/day, with tonic seizures on abrupt discontinuation in both patients.supported
Two cases: doses 200-400 mg/night and 400-500 mg/day for euphoria. Abrupt discontinuation produced anxiety, insomnia, restlessness, tonic seizure. Asian population. pmid:21448102
Victorri-Vigneau et al. found that 45.3% of elderly patients prescribed benzodiazepines or Z-drugs for ≥3 months met DSM dependence criteria, with Z-drugs including zolpidem contributing to this prevalence.supported
45.3% of 1,024 elderly patients on BZD/Z-drugs for >=3 months met DSM dependence criteria. cpt.2025
Claim in safety — inconclusiveinconclusiveworking →
Hojo et al. confirmed that St. John's Wort significantly reduces zolpidem plasma exposure in healthy subjects.supported
St John's Wort (CYP3A4 inducer) alters pharmacokinetics of zolpidem. Clinical DDI study in healthy subjects. j.1365-2710.2010.01223.x
Alcohol: Enhanced sedation and respiratory depression; potentially lethal.supported
Voluntary intoxication with zolpidem, prothipendyl, and ethanol. Flumazenil corrected respiratory depression. pmid:1675298
Imipramine: Potentiated anterograde amnesia documented in controlled volunteer studies.supported
Anterograde amnesia noted with imipramine combination. pmid:8521677
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Active substance use disorders (relative) — documented abuse potential at supratherapeutic dosessupported
Zolpidem at 15 and 30mg produced dose-related effects on 'high' VAS, euphoric mood, and hallucination in recreational polydrug users. Higher doses had greater abuse potential measures. jcp.0000000000000516
Claim in safety — inconclusiveinconclusiveworking →
Elderly (use with caution) — disproportionate fall/fracture risk; reduced clearance; dose reduction to 5 mg recommendedsupported
Meta-analysis: sedative hypnotics including zolpidem improve sleep statistically but magnitude small. Increased adverse event risk (falls, cognitive impairment) in over-60s. bmj.38623.768588.47
pharmacology25 · 18 ok
Unlike classical benzodiazepines, zolpidem displays strong preferential affinity for GABA-A receptors containing the α1 subunit (α1β2γ2 configuration, designated BZ₁ or omega-1)supported
Zolpidem is alpha1 selective in vivo: ID50 10 mg/kg (cerebellum, alpha1-rich) vs >30 mg/kg (spinal cord, alpha2/3-rich). Confirms omega-1 binding preference. pmid:10063485
Unlike classical benzodiazepines, zolpidem displays strong preferential affinity for GABA-A receptors containing the α1 subunit (α1β2γ2 configuration, designated BZ₁ or omega-1)supported
Z-drugs selectivity: zopiclone/zolpidem/zaleplon preferentially interact with omega-1 receptors (sedation) vs omega-2 (memory/cognition adverse effects). pmid:12608888
Unlike classical benzodiazepines, zolpidem displays strong preferential affinity for GABA-A receptors containing the α1 subunit (α1β2γ2 configuration, designated BZ₁ or omega-1)supported
Substitution of Gly201 in a1 with Glu in a3 completely eliminated zolpidem's a1-over-a3 preference. Key molecular determinants of zolpidem subtype selectivity identified. j.bcp.2018.08.019
In vivo, zolpidem occupied α1-rich cerebellar benzodiazepine sites at an ID₅₀ of ~10 mg/kg (i.p., mice), versus >30 mg/kg for α2/α3-rich spinal cord tissue.supported
Zolpidem is alpha1 selective in vivo: ID50 10 mg/kg (cerebellum, alpha1-rich) vs >30 mg/kg (spinal cord, alpha2/3-rich). pmid:10063485
High-resolution cryo-EM structural work confirmed that zolpidem binds at the classic extracellular benzodiazepine site at the α/γ interface and at two additional transmembrane sites located at β/α interfacessupported
Both drugs share the extracellular benzodiazepine site at the alpha/gamma subunit interface and two transmembrane sites at beta/alpha interfaces. s41467-022-32212-4
Substitution of this residue completely abolished the α1-over-α3 preferencesupported
Substitution of Gly201 in a1 with Glu in a3 completely eliminated zolpidem's a1-over-a3 preference. j.bcp.2018.08.019
Dixon et al. demonstrated that zolpidem "primes" α1β2γ2 GABA-A receptors for longer activity durations — a mechanistic feature distinct from classical benzodiazepines that may explain aspects of its clinical profile.supported
Investigates mechanism by which zolpidem enhances activity of a1b2g2 GABA-A receptors; finds priming for longer duration of activity. bph.13142
Flumazenil, a BZ site antagonist, fully reverses zolpidem's effects — confirming shared binding-site occupancy with classical benzodiazepinessupported
Not reversed by naloxone; dramatically reversed by flumazenil. pmid:2111156
Claim in pharmacology — inconclusiveinconclusiveworking →
The α1 selectivity underlies clinical differentiation: sedative and hypnotic effects (omega-1/α1-mediated) predominate at therapeutic doses, while anxiolytic, myorelaxant, and anticonvulsant effects (requiring α2, α3, or α5 subtypes) remain minimal.supported
Z-drugs selectivity: zopiclone/zolpidem/zaleplon preferentially interact with omega-1 receptors (sedation) vs omega-2 (memory/cognition adverse effects). pmid:12608888
The hypothesized mechanism involves reversal of pathological GABAergic over-inhibition (diaschisis) or restoration of cortical excitation-inhibition balancesupported
CNS depressants including zolpidem can promote consciousness recovery in vegetative/minimally conscious state. Hypothesizes reversal of GABA impairment in injured brain. pmid:24025066
Zolpidem is rapidly absorbed following oral administration, with bioavailability of approximately 70%supported
Bioavailability ~70%. pmid:8521677
Peak plasma concentrations occur at a median Tmax of ~1.6 hours (range 0.75–2.6 hours) for the immediate-release formulationsupported
Tmax 0.75-2.6h after 20mg. pmid:8521677
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Elimination half-life in the general population is 1.5–3.2 hours, with sex-based differences: approximately 4.4 hours in women versus 3.3 hours in men at 5 mg.partially supported
t1/2 1.5-3.2h after 20mg. pmid:8521677
Elimination half-life in the general population is 1.5–3.2 hours, with sex-based differences: approximately 4.4 hours in women versus 3.3 hours in men at 5 mg.supported
Sex differences in PK at 5mg: women AUC 604.34 ng*h/ml, t1/2 4.4h vs men AUC 276.1 ng*h/ml, t1/2 3.3h. bmc.4731
Women achieve approximately 50% higher plasma Cmax and approximately 2-fold higher AUC than men at equivalent dosespartially supported
Sex differences in PK at 5mg: women AUC 604.34 ng*h/ml, t1/2 4.4h vs men AUC 276.1 ng*h/ml, t1/2 3.3h. bmc.4731
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
All metabolites are pharmacologically inactive; no active metabolites of clinical significance have been identified.supported
No active metabolites. pmid:8521677
Zolpidem does not induce CYP1A1, CYP1A2, CYP2C9, or CYP3A4 expression in human hepatocytes at therapeutic or supratherapeutic concentrations, and does not activate aryl hydrocarbon receptor (AhR) or pregnane X receptor (PXR)supported
Zolpidem does not alter CYP1A1, CYP1A2, CYP2C9 or CYP3A4 mRNA in human hepatocytes; does not activate AhR or PXR. j.toxlet.2009.08.009
CYP2D6 genotype (poor, intermediate, or extensive metabolizer) does not significantly alter zolpidem plasma exposure, consistent with CYP2D6's minor (<3%) metabolic contributionsupported
CYP2D6 genotype does not significantly affect zolpidem exposure. s12272-020-01250-1
Claim in pharmacology — inconclusiveinconclusiveworking →
clinical-evidence12 · 7 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Staner et al. conducted a randomized trial comparing sublingual versus oral zolpidem 10 mg and demonstrated that the sublingual route achieved earlier sleep onset, attributed to faster absorption and partial avoidance of hepatic first-pass metabolismsupported
Sublingual zolpidem 5 and 10mg vs oral zolpidem 10mg; sublingual achieves faster sleep onset. j.sleep.2008.06.008
Roth et al. established the efficacy of low-dose sublingual zolpidem tartrate (1.75 mg and 3.5 mg) for middle-of-the-night awakenings, showing dose-related improvement in sleep onset and duration in patients with insomnia characterized by nocturnal waking.supported
Low-dose sublingual zolpidem for middle-of-the-night insomnia; dose-related improvements in sleep onset and duration. pmid:18788653
Zolpidem 10 mg increases sleep spindle density and sigma power on EEG while suppressing delta/slow-wave activity; REM sleep is not significantly affectedpartially supported
Zolpidem 10mg increased spindle density; attenuated caffeine-induced sleep efficiency decrease. No significant changes in REM sleep or slow wave activity. 0269881109104852
Zolpidem 10 mg increases sleep spindle density and sigma power on EEG while suppressing delta/slow-wave activity; REM sleep is not significantly affectedpartially supported
Zolpidem 10mg: depresses delta and REM, stimulates sigma (spindles) and beta EEG. pmid:11104841
Kleykamp et al. conducted a randomized, double-blind study of zolpidem extended-release 12.5 mg administered nightly to healthy males over approximately one monthsupported
ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use. a0025237
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
The European Insomnia Guideline similarly endorses short-term use (≤4 weeks) of zolpidem within the pharmacotherapy hierarchy.supported
CBT-I recommended first-line. Benzodiazepines and BZRAs (including zolpidem) can be used short-term (<=4 weeks). Longer-term use may be initiated in some cases weighing risks/benefits. jsr.14035
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Monti et al. conducted a double-blind, controlled polysomnographic study in chronic insomniac patients treated with zolpidem for 27 consecutive nightssupported
27-night RCT: zolpidem 10mg vs triazolam 0.5mg vs placebo. Zolpidem effective; no rebound insomnia on withdrawal (unlike triazolam); no tolerance detected. pmid:7972349
Claim in clinical-evidence — inconclusiveinconclusiveworking →
pharmacokinetic-detail11 · 7 ok
Extended-release (ER): Dual-layer tablet (6.25 mg, 12.5 mg) delivering an initial immediate-release bolus plus a sustained-release component. Extends sleep maintenance versus IR formulation.supported
Zolpidem CR (12.5mg adults, 6.25mg elderly): significantly improved sleep latency, WASO, and sleep efficiency vs placebo in two Phase III polysomnography trials. Dual-layer tablet design. pmid:16696581
Sublingual: Sublingual tablet (Edluar, 5 mg, 10 mg) and sublingual-in-bed formulation (Intermezzo, 1.75 mg, 3.5 mg). Staner et al. demonstrated that sublingual zolpidem achieves earlier onset of sleep versus oral administration due to faster absorption and partial avoidance of first-pass metabolism. Roth et al. confirmed the efficacy of low-dose sublingual zolpidem (1.75–3.5 mg) for middle-of-the-night awakenings.supported
Sublingual zolpidem 5 and 10mg vs oral zolpidem 10mg; sublingual achieves faster sleep onset. j.sleep.2008.06.008
Sublingual: Sublingual tablet (Edluar, 5 mg, 10 mg) and sublingual-in-bed formulation (Intermezzo, 1.75 mg, 3.5 mg). Staner et al. demonstrated that sublingual zolpidem achieves earlier onset of sleep versus oral administration due to faster absorption and partial avoidance of first-pass metabolism. Roth et al. confirmed the efficacy of low-dose sublingual zolpidem (1.75–3.5 mg) for middle-of-the-night awakenings.supported
Low-dose sublingual zolpidem for middle-of-the-night insomnia; dose-related improvements in sleep onset and duration. pmid:18788653
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Women achieve approximately 50% higher Cmax and approximately 2-fold higher AUC than men at equivalent oral dosespartially supported
Sex differences in PK at 5mg: women AUC 604.34 ng*h/ml, t1/2 4.4h vs men AUC 276.1 ng*h/ml, t1/2 3.3h. Statistically significant differences in all PK parameters. bmc.4731
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
All metabolites are pharmacologically inactivesupported
No active metabolites. pmid:8521677
Zolpidem does not induce CYP1A1, CYP1A2, CYP2C9, or CYP3A4 expression in human hepatocytes and does not activate AhR or PXR, indicating low potential for enzyme-induction-mediated drug interactions when zolpidem is the perpetrator drug.supported
Zolpidem does not alter CYP1A1, CYP1A2, CYP2C9 or CYP3A4 mRNA in human hepatocytes; does not activate AhR or PXR. Considered safe re: CYP induction interactions. j.toxlet.2009.08.009
St. John's Wort (Hypericum perforatum), a potent CYP3A4 inducer, significantly reduces zolpidem plasma exposure in healthy subjectssupported
St John's Wort (CYP3A4 inducer) alters pharmacokinetics of zolpidem. Clinical DDI study in healthy subjects. j.1365-2710.2010.01223.x
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
summary11 · 8 ok
Physical dependence with withdrawal seizures is documented at high doses (200–500 mg/day)supported
Two cases: doses 200-400 mg/night and 400-500 mg/day for euphoria. Abrupt discontinuation produced anxiety, insomnia, restlessness, tonic seizure. pmid:21448102
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Zolpidem's pharmacological signature is strong preferential affinity for α1 subunit-containing GABA-A receptors (BZ₁/omega-1), confirmed by cryo-EM structural work and traced to a single residue — Gly201 on the α1 subunit versus Glu225 on α3supported
Structural analyses reveal basis for subtype selectivity of zolpidem. s41467-022-32212-4
Zolpidem's pharmacological signature is strong preferential affinity for α1 subunit-containing GABA-A receptors (BZ₁/omega-1), confirmed by cryo-EM structural work and traced to a single residue — Gly201 on the α1 subunit versus Glu225 on α3supported
Substitution of Gly201 in a1 with Glu in a3 completely eliminated zolpidem's a1-over-a3 preference. j.bcp.2018.08.019
At supratherapeutic doses (≥15 mg), euphoria, hallucinations, and perceptual distortions emerge dose-dependentlysupported
Zolpidem at 15 and 30mg produced dose-related effects on 'high' VAS, euphoric mood, and hallucination in recreational polydrug users. jcp.0000000000000516
Claim in summary — inconclusiveinconclusiveworking →
Single-agent acute toxicity is low; overdose presents as short-lasting coma reversible by flumazenilsupported
Profound but short-lasting coma, pinpoint pupils, respiratory depression. Not reversed by naloxone; dramatically reversed by flumazenil. pmid:2111156
Tolerance to hypnotic effects does not develop over 27 nights at therapeutic doses, yet tolerance to cognitive and psychomotor impairments during nighttime awakening also fails to develop — producing persistent functional impairment throughout treatmentpartially supported
27-night RCT: zolpidem 10mg vs triazolam 0.5mg vs placebo. Zolpidem effective; no rebound insomnia on withdrawal (unlike triazolam); no tolerance detected. pmid:7972349
Tolerance to hypnotic effects does not develop over 27 nights at therapeutic doses, yet tolerance to cognitive and psychomotor impairments during nighttime awakening also fails to develop — producing persistent functional impairment throughout treatmentsupported
ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use. a0025237
The molecular mechanism involves functional uncoupling of GABA and benzodiazepine binding sites rather than receptor downregulationsupported
Chronic zolpidem treatment and withdrawal induced functional uncoupling between GABA and benzodiazepine binding sites; receptor upregulation and subunit mRNA changes after 96h withdrawal. ane-2015-2025
comparative-pharmacology9 · 5 ok
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Dependence: Both classes produce physical dependence with chronic use, though zolpidem's dependence liability at therapeutic doses is lower. Wright et al. demonstrated in mice that repeated zolpidem produces behavioral tolerance and withdrawal-like symptoms similar to diazepam, challenging the assumption of categorically lower dependence risk.supported
Repeated zolpidem produces tolerance and withdrawal-like symptoms similar to benzodiazepines despite purported lower dependence. Mouse model. s00213-014-3473-x
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Zolpidem's α1 selectivity restricts its primary pharmacological action to sedation and sleep induction.supported
Z-drugs selectivity: zopiclone/zolpidem/zaleplon preferentially interact with omega-1 receptors (sedation) vs omega-2 (memory/cognition adverse effects). pmid:12608888
Tolerance: Zolpidem shows no hypnotic tolerance over 27 nights, whereas triazolam develops tolerance in comparable study designs.supported
27-night RCT: zolpidem 10mg vs triazolam 0.5mg vs placebo. Zolpidem effective; no rebound insomnia on withdrawal (unlike triazolam); no tolerance detected. pmid:7972349
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Inoue et al. further compared the two agents across insomnia disorder subtypes and found differential effectiveness depending on the phenotype (sleep-onset versus sleep-maintenance insomnia).supported
Differences in response to lemborexant vs zolpidem ER 6.25mg across insomnia phenotypes (short vs normal sleep duration). jcsm.10378
Liu et al. conducted a Bayesian network meta-regression integrating clinical trial efficacy data with FAERS-based safety analysis across insomnia pharmacotherapiessupported
Network meta-analysis and FAERS analysis comparing DORAs, benzodiazepines, Z-drugs and melatonin agonists for insomnia. j.sleep.2025.106848
neuroscience8 · 5 ok
Zolpidem 10 mg increases sleep spindle density and sigma power on polysomnography, consistent with enhanced TRN inhibitory output to thalamocortical relay neuronssupported
Zolpidem 10mg increased spindle density. 0269881109104852
Zolpidem 10 mg increases sleep spindle density and sigma power on polysomnography, consistent with enhanced TRN inhibitory output to thalamocortical relay neuronssupported
Zolpidem 10mg: depresses delta and REM, stimulates sigma (spindles) and beta EEG. pmid:11104841
Claim in neuroscience — inconclusiveinconclusiveworking →
This selective memory impairment persists throughout treatment without tolerance development.supported
ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use. a0025237
The paradoxical consciousness-promoting effect of zolpidem in patients with severe brain injury — termed the "zolpidem response" — involves a fundamentally different neural mechanismsupported
CNS depressants including zolpidem can promote consciousness recovery in vegetative/minimally conscious state. Hypothesizes reversal of GABA impairment in injured brain. pmid:24025066
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Tolerance dissociation: Why tolerance develops to sedative effects at high doses but not to cognitive/psychomotor impairment during nighttime awakening at therapeutic doses is mechanistically unexplained. The receptor-level mechanism may involve distinct populations of α1-containing GABA-A receptors in sleep-promoting versus cognitive circuits.supported
ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use. a0025237
receptor-pharmacology6 · 5 ok
In vivo selectivity was confirmed by Atack et al. using displacement of [³H]Ro 15-1788 binding in mice: zolpidem occupied α1-rich cerebellar benzodiazepine sites at an ID₅₀ of approximately 10 mg/kg (i.p.), versus >30 mg/kg for α2/α3-rich spinal cord tissue — a selectivity ratio exceeding 3:1 in vivo.supported
Zolpidem is alpha1 selective in vivo: ID50 10 mg/kg (cerebellum, alpha1-rich) vs >30 mg/kg (spinal cord, alpha2/3-rich). pmid:10063485
The affinity hierarchy α1 >> α2 ≈ α3 > α5 is consistently reported across the literature, though specific Ki values at human recombinant GABA-A receptor subtypes were not recovered from primary sources in this reviewsupported
Zolpidem is alpha1 selective in vivo: ID50 10 mg/kg (cerebellum, alpha1-rich) vs >30 mg/kg (spinal cord, alpha2/3-rich). pmid:10063485
The affinity hierarchy α1 >> α2 ≈ α3 > α5 is consistently reported across the literature, though specific Ki values at human recombinant GABA-A receptor subtypes were not recovered from primary sources in this reviewsupported
Z-drugs selectivity: zopiclone/zolpidem/zaleplon preferentially interact with omega-1 receptors (sedation) vs omega-2 (memory/cognition adverse effects). pmid:12608888
Söderhielm et al. systematically probed the molecular determinants of zolpidem's subtype selectivity using mutagenesis and electrophysiological recording at recombinant GABA-A receptorssupported
Substitution of Gly201 in a1 with Glu in a3 completely eliminated zolpidem's a1-over-a3 preference. Key molecular determinants of zolpidem subtype selectivity identified. j.bcp.2018.08.019
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Flumazenil, a competitive antagonist at the benzodiazepine binding site, fully reverses zolpidem's allosteric potentiation, confirming that the drug's primary pharmacological action occurs through classical BZ-site occupancy.supported
Not reversed by naloxone; dramatically reversed by flumazenil. pmid:2111156
chemistry1 · 0 ok
Claim in chemistry — inconclusiveinconclusiveworking →
history1 · 1 ok
By the early 2000s, Ambien had become the most widely prescribed hypnotic drug in the United States.supported
Zolpidem (imidazopyridine) is most widely prescribed hypnotic in US. 14656566.2012.667074